This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Press and hold the button
If you believe this is an error, please contact our support team.
192.64.82.12 : 8215984a-b828-41af-886b-3035bd0e
A comparison of two risk prediction tools used to calculate an individual’s risk of developing cardiovascular disease (CVD) suggests that the long-term, 30-year risk should be considered in addition to
Credit: Anna Shvets from Pexels Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research
Potassium supplementation at a threshold of published online Aug. 31 in the Journal of the American Medical Association to coincide with the European Society of Cardiology Congress 2024, held from
